BioCryst Pharmaceuticals Inc (BCRX)
8.43
+0.42
(+5.24%)
USD |
NASDAQ |
Nov 01, 16:00
8.50
+0.07
(+0.83%)
After-Hours: 20:00
BioCryst Pharmaceuticals Total Liabilities (Quarterly): 948.02M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 948.02M |
| March 31, 2024 | 944.06M |
| December 31, 2023 | 972.49M |
| September 30, 2023 | 933.91M |
| June 30, 2023 | 918.60M |
| March 31, 2023 | 838.02M |
| December 31, 2022 | 844.60M |
| September 30, 2022 | 801.25M |
| June 30, 2022 | 723.77M |
| March 31, 2022 | 691.94M |
| December 31, 2021 | 695.14M |
| September 30, 2021 | 412.81M |
| June 30, 2021 | 383.36M |
| March 31, 2021 | 359.42M |
| December 31, 2020 | 353.98M |
| September 30, 2020 | 142.59M |
| June 30, 2020 | 138.20M |
| March 31, 2020 | 132.94M |
| December 31, 2019 | 137.03M |
| September 30, 2019 | 131.75M |
| June 30, 2019 | 125.54M |
| March 31, 2019 | 119.83M |
| December 31, 2018 | 97.61M |
| September 30, 2018 | 95.44M |
| June 30, 2018 | 90.46M |
| Date | Value |
|---|---|
| March 31, 2018 | 93.32M |
| December 31, 2017 | 94.49M |
| September 30, 2017 | 90.86M |
| June 30, 2017 | 89.43M |
| March 31, 2017 | 90.98M |
| December 31, 2016 | 88.27M |
| September 30, 2016 | 87.51M |
| June 30, 2016 | 68.83M |
| March 31, 2016 | 75.08M |
| December 31, 2015 | 74.64M |
| September 30, 2015 | 74.91M |
| June 30, 2015 | 74.09M |
| March 31, 2015 | 65.50M |
| December 31, 2014 | 61.24M |
| September 30, 2014 | 53.67M |
| June 30, 2014 | 51.89M |
| March 31, 2014 | 49.11M |
| December 31, 2013 | 49.99M |
| September 30, 2013 | 49.80M |
| June 30, 2013 | 48.96M |
| March 31, 2013 | 49.74M |
| December 31, 2012 | 57.89M |
| September 30, 2012 | 54.31M |
| June 30, 2012 | 60.58M |
| March 31, 2012 | 56.94M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
132.94M
Minimum
Mar 2020
972.49M
Maximum
Dec 2023
598.53M
Average
695.14M
Median
Dec 2021
Total Liabilities (Quarterly) Benchmarks
| Novavax Inc | 2.250B |
| AIM ImmunoTech Inc | 9.613M |
| Perspective Therapeutics Inc | 44.92M |
| Protalix BioTherapeutics Inc | 62.96M |
| Armata Pharmaceuticals Inc | 154.41M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 472.42M |
| Shareholders Equity (Quarterly) | -475.61M |
| Debt to Equity Ratio | -1.700 |
| Current Ratio | 2.816 |
| Net Debt Paydown Yield | -0.96% |